Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.
All patients with sustained minimal residual disease (MRD) negativity lasting 6 months or longer achieved stringent complete response after infusion with the chimeric antigen receptor T-cell therapy, a subgroup analysis from the CARTITUDE-1 trial presented at Society of Hematologic Oncology Annual Meeting showed.
“Patients treated on this study with a single dose of
